Arrowhead Pharmaceuticals, Inc. (ARWR) Business Profile

What it does

Arrowhead Pharmaceuticals develops medicines that silence genes associated with disease. Its treatments use RNA interference, a process in living cells that can reduce production of a selected protein. Arrowhead designs small RNA molecules to reach particular tissues and trigger that process.

Its first approved medicine, REDEMPLO, is used alongside diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare condition associated with very high levels of fats in the blood. REDEMPLO is designed to suppress production of APOC3, a protein that slows the breakdown and clearance of triglycerides. Common adverse reactions include hyperglycemia, headache, nausea and injection-site reactions.

Arrowhead also develops candidates for other conditions, including severe hypertriglyceridemia, inherited high cholesterol, obesity, kidney diseases and Alzheimer’s disease. Its TRiM platform combines an RNA trigger with components intended to deliver it to a selected tissue. Arrowhead develops some programs for itself and licenses others to pharmaceutical companies for further development or commercialization.

Founded in 1989, Arrowhead is headquartered in Pasadena, California. It operates research laboratories in California and Wisconsin. At the time of its fiscal 2025 annual report, the company had 18 discovered drug candidates in clinical trials, from early-stage through Phase 3 studies.

How it makes money

Arrowhead earns money from sales of REDEMPLO and from licensing and collaboration agreements. Its partners obtain rights to particular drug candidates or research programs; depending on the agreement, Arrowhead can receive upfront payments, payments when development or sales milestones are reached, reimbursement for certain work, and royalties on future product sales. Milestones depend on the terms and progress of each program rather than arriving on a fixed sales schedule.

For the quarter ended June 30, 2026, revenue was approximately $75 million and the net loss was $194.3 million. Revenue included approximately $2.4 million in commercial sales, with the rest of the business supported by collaboration revenue. Arrowhead recognized approximately $26 million related to Sarepta, mainly from recognizing initial consideration and reimbursement of certain clinical and manufacturing expenses.

The company’s arrangements differ in how rights and proceeds are shared. Takeda and Arrowhead co-develop fazirsiran for liver disease associated with alpha-1 antitrypsin deficiency. If approved, it will be co-commercialized in the United States under a 50/50 profit-sharing structure; outside the United States, Takeda has exclusive commercialization rights and Arrowhead is eligible for tiered royalties of 20% to 25% on net sales.

Arrowhead also licensed ARO-PNPLA3 worldwide to Madrigal. It received $25 million upfront and remains eligible for up to $975 million in development, regulatory and sales milestones, plus tiered royalties on future sales. By contrast, Royalty Pharma is entitled to receive the olpasiran royalties otherwise payable by Amgen to Arrowhead, although Arrowhead remains eligible for certain milestone payments.

Customers and how it sells

REDEMPLO is prescribed for adults with FCS, including patients diagnosed clinically or through genetic testing. Physicians and third-party payers have roles in recommending, prescribing and paying for medicines. Arrowhead reported that it had supported more than 400 unique REDEMPLO prescribers, led by preventive cardiology and endocrinology, and that nearly all published payer policies allowed physicians to diagnose FCS using clinical criteria alone.

The United States was the company’s first commercial market. The European Commission subsequently authorized REDEMPLO for adults with FCS diagnosed clinically or genetically, and Australia approved it for the same patient groups. It was reported on 28 October 2026 that REDEMPLO was approved and reimbursed on the NHS in England for people with FCS. Sanofi leads commercialization in Greater China, while Arrowhead works through country-specific reimbursement and launch processes elsewhere.

Pharmaceutical companies are also customers and partners for Arrowhead’s technology. Sarepta has rights to programs in rare genetic diseases of muscle, the central nervous system and lungs. Novartis licensed a preclinical program for synucleinopathies, including Parkinson’s disease, and additional research targets. The company’s agreements allocate development and commercialization responsibilities differently by program and territory.

Suppliers and costs

Arrowhead conducts research and development in its California and Wisconsin laboratories. It manufactures drug materials for studies and clinical trials internally or contracts the work to outside manufacturers. It also uses outside laboratories for toxicology studies and contract research organizations to help manage trials, including study design, patient recruitment and follow-up.

The company groups outside testing, manufacturing and clinical-trial preparation and administration expenses as candidate costs. Arrowhead expects those costs to rise as candidates advance through clinical development. It also needs supply arrangements with third-party drug-product suppliers and manufacturers, including scaled production and packaging arrangements for products sold commercially.

For the quarter ended June 30, 2026, operating expenses were approximately $245 million, including approximately $198 million in research and development and approximately $47 million in selling, general and administrative expenses. Higher research spending included candidate costs, manufacturing and clinical-supply activity, while commercial spending included headcount, marketing and launch support. Arrowhead expects active execution costs for SHASTA-3 and SHASTA-4 to begin moderating in fiscal 2027, while it continues to invest in regulatory work, commercial supply readiness and its broader pipeline.

Competitive position

Arrowhead competes for patients, prescribers and payer coverage with other therapies. The company has described patients switching to REDEMPLO from a competitor’s APOC3 inhibitor, without naming that product. In Alzheimer’s disease, Biogen and Ionis have an antisense program targeting MAPT; Arrowhead is developing its own ARO-MAPT candidate for Alzheimer’s disease and other tauopathies.

Arrowhead’s TRiM platform uses targeting ligands and RNA triggers selected with proprietary rules and algorithms. The company says the platform enables delivery to seven cell types. It controls approximately 643 issued patents and approximately 833 pending patent applications worldwide, covering areas including RNA triggers and delivery technologies. Arrowhead also notes that the RNAi and delivery patent landscapes are complex and that it may need additional licenses before commercializing candidates.

Our reading: The platform and patent portfolio give Arrowhead a potential technology barrier across programs, but its strength depends on enforceable protection and successful delivery in patients. Our reading: REDEMPLO’s approval and commercial organization give Arrowhead an established position in FCS, although competing therapies and payer access can still affect adoption. The evidence available does not establish comparative market shares for these companies or products.

Growth opportunities

Arrowhead is seeking to expand REDEMPLO beyond FCS into severe hypertriglyceridemia, a condition involving elevated triglycerides. The company estimates that more than 1 million high-risk patients in the United States have severe hypertriglyceridemia, compared with an estimated 6,500 people with genetic or clinical FCS. Arrowhead plans a supplemental application for the broader indication, subject to the clinical and regulatory process.

Arrowhead reported that SHASTA-3 and SHASTA-4 met their primary and prespecified secondary endpoints. It reported median triglyceride reductions from baseline at month 12 of 79% and 81%, respectively, compared with approximately 27% for placebo. The company said SHASTA-5 was continuing without changes.

Other programs could extend the business into additional diseases. Arrowhead completed enrollment in the Phase 3 YOSEMITE study of zodasiran for homozygous familial hypercholesterolemia. Its ARO-DIMER-PA candidate is designed to silence two genes associated with cholesterol and triglycerides; Arrowhead estimates that roughly 20 million people in the United States have both elevated LDL cholesterol and triglycerides. Its ARO-MAPT study is enrolling people with Alzheimer’s disease.

Licensing is another route for advancing programs. Under its Madrigal agreement, Arrowhead is eligible for development, regulatory and sales milestones and royalties if the licensed ARO-PNPLA3 program progresses and reaches the market.

Structural risks

• Clinical development and approval: Arrowhead’s prospects depend substantially on its clinical-stage candidates. Early study results may not predict later results, and candidates may have undesirable effects or fail to obtain approval.
• Commercial acceptance: Successful sales depend on acceptance by patients, medical professionals and payers, as well as Arrowhead’s ability to compete with other therapies and establish sales, marketing and distribution capabilities.
• Manufacturing and supply: Development and commercialization depend on adequate internal manufacturing capabilities and arrangements with outside suppliers and manufacturers. Regulatory problems at facilities can lead to restrictions, recalls or refusal of approval.
• Intellectual property: Arrowhead cannot guarantee that its issued patents will be enforceable or provide adequate protection, or that pending applications will become patents. It may need additional licenses before commercializing candidates.
• Partners: Collaborators may devote insufficient resources to programs, develop competing technologies, or terminate agreements prematurely. Some agreements also limit what Arrowhead can develop independently.
• Financial resources: Arrowhead has a history of net losses and expects to continue incurring them; it may not achieve or maintain profitability. Research, development and commercialization require substantial cash expenditure.

Bottom line

Our reading

Arrowhead combines an approved rare-disease medicine with a pipeline built on gene-silencing technology and a network of licensing partners [item1]. Its near-term commercial development depends on REDEMPLO adoption and the outcome of the proposed expansion into severe hypertriglyceridemia, while many other programs remain in development [item1, facts]. Collaboration payments help fund the business, but milestones depend on program progress and the company continues to incur substantial operating expenses and losses [call_prepared, item1a].